Formulation, characterisation and stability assessment of a food derived 1 tripeptide, Leucine-Lysine-Proline loaded chitosan nanoparticles

The chicken or fish derived tripeptide, Leucine-Lysine-Proline (LKP), inhibits the Angiotensin Converting Enzyme and may be used as an alternative treatment for pre-hypertension. However, it has low permeation across the small intestine. The formulation of LKP into a nanoparticle (NP) has the potential to address this issue. LKP-loaded NPs were produced using an ionotropic gelation technique, using chitosan (CL113). Following optimisation of unloaded NPs, a mixture amount design was constructed using variable concentration of CL113 and tripolyphosphate at a fixed LKP concentration. Resultant particle sizes ranged from 120-271 nm, zeta potential values from 29-37 mV and polydispersity values from 0.3-0.6. A ratio of 6:1 (CL113: TPP) produced the best encapsulation of approximately 65%. Accelerated studies of the loaded nanoparticles indicated stability under normal storage conditions (room temperature). Cytotoxicity assessment showed no significant loss of cell viability and in vitro release studies indicated an initial burst followed by a slower and sustained release

Potential of Saudi natural clay as an effective adsorbent in heavy metals removal from wastewater

NoThis study aims to examine the potential of natural clay mineral from the southern part of Saudi Arabia as an effective adsorbent material for the removal of heavy metal ions of cadmium (Cd) and nickel (Ni) from aqueous solutions. The SEM analysis showed that clay particles had mixed shapes such as elongated rod-like and rectangular shape having rough corners with larger particles of 2-8 µm in size and smaller particles in the sub-micron size range. X-ray diffraction data revealed that clay particles had a good crystalline structure and composed of a mixture of various minerals including feldspar, illite, quartz, calcite, and gypsum. The BET surface area was found to be 35 ± 1 m ² /g and the average pore size and pore volume of 6.5 ± 0.5 nm and 5.7e-02 cc/g, respectively. The X-ray fluorescence analysis of clay showed main compounds of SiO₂ (47.33%), Al₂O₃ (18.14%), Fe₂O₃ (15.89%) with many others such as CaO, MgO, TiO₂, and K₂O in minor quantities. It was found that 1.2 g of clay removed up to 99.5% of Ni and 97.5% of Cd from 40 ppm aqueous solutions. The metal removal efficiencies were increased from around 95% up to 99% by increasing the pH of aqueous solutions from 4 to 11. The adsorption of Ni and Cd ions on Saudi clay was relatively fast, and up to 97% of ions were removed from solution within 45 min. The SEM-EDX and BET analysis for recycled clays further confirmed that the metal ions were removed from water through adsorption onto the clay. The experimental data fitted well with Langmuir and Freundlich isotherms. The maximum adsorption capacity of clay for Cd and Ni from isotherms was found to be 3.3 and 2.7 mg/g respectively. The findings of this study confirm the potential role of Saudi natural clay in wastewater treatment processes as a cheap, environment-friendly and safe natural adsorbent material.The authors extend their appreciation to the Deanship of Scientific Research at King Khalid University for funding this work through research groups program under grant number R.G.P1./97/40

Causal effect of plasminogen activator inhibitor type 1 on coronary heart disease

Background--Plasminogen activator inhibitor type 1 (PAI-1) plays an essential role in the fibrinolysis system and thrombosis. Population studies have reported that blood PAI-1 levels are associated with increased risk of coronary heart disease (CHD). However, it is unclear whether the association reflects a causal influence of PAI-1 on CHD risk. Methods and Results--To evaluate the association wbetween PAI-1 and CHD, we applied a 3-step strategy. First, we investigated the observational association between PAI-1 and CHD incidence using a systematic review based on a literature search for PAI-1 and CHD studies. Second, we explored the causal association between PAI-1 and CHD using a Mendelian randomization approach using summary statistics from large genome-wide association studies. Finally, we explored the causal effect of PAI-1 on cardiovascular risk factors including metabolic and subclinical atherosclerosis measures. In the systematic meta-analysis, the highest quantile of blood PAI-1 level was associated with higher CHD risk comparing with the lowest quantile (odds ratio=2.17; 95% CI: 1.53, 3.07) in an age- and sex-adjusted model. The effect size was reduced in studies using a multivariable-adjusted model (odds ratio=1.46; 95% CI: 1.13, 1.88). The Mendelian randomization analyses suggested a causal effect of increased PAI-1 level on CHD risk (odds ratio=1.22 per unit increase of log-transformed PAI-1; 95% CI: 1.01, 1.47). In addition, we also detected a causal effect of PAI-1 on elevating blood glucose and high-density lipoprotein cholesterol. Conclusions--Our study indicates a causal effect of elevated PAI-1 level on CHD risk, which may be mediated by glucose dysfunction